Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Fiche publication
Date publication
octobre 2023
Journal
European urology oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Dr GEOFFROIS Lionnel, Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G
Lien Pubmed
Résumé
Glandular metastases (GMs; adrenal gland, pancreas, thyroid, ovary, breast, or prostate) are rare in metastatic clear cell renal cell carcinoma (mccRCC). Previous studies have indicated that GM patients treated with antiangiogenic therapy experience significantly longer overall survival (OS).
Mots clés
Adrenal metastases, GETUG-AFU-26 NIVOREN trial, Glandular metastases, Immunotherapy, Nivolumab, Pancreatic metastases, Renal cell carcinoma
Référence
Eur Urol Oncol. 2023 10 7;: